|ATC code||G03DB07 (WHO)|
|Chemical and physical data|
|Molar mass||326.472 g/mol|
|3D model (Jmol)||Interactive image|
Promegestone (INN) (brand name Surgestone), also known as 17α,21-dimethyl-Δ9-19-norprogesterone or 17α,21-dimethyl-19-norpregna-4,9-diene-3,20-dione, is a steroidal progestin of the 19-norprogesterone group which was introduced in 1983 and is marketed in France, Portugal, and Argentina. Indications include gynaecological conditions caused by luteal insufficiency, including premenopausal disorders, dysmenorrhea, and premenstrual syndrome. Promegestone has weak glucocorticoid activity, but does not bind to the androgen receptor or possess antimineralocorticoid activity. In addition, promegestone has been found to act as a non-competitive antagonist of the nicotinic acetylcholine receptor, similarly to progesterone. The drug is mainly bound to albumin; it does not bind to sex hormone-binding globulin, and binds only weakly to transcortin.
- J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 1026–. ISBN 978-1-4757-2085-3.
- William Andrew Publishing (22 October 2013). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
- Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 883–. ISBN 978-3-88763-075-1.
- Cain (11 September 1984). ANNUAL REPORTS IN MED CHEMISTRY V19 PPR. Academic Press. pp. 323–. ISBN 978-0-08-058363-1.
- Kuhl, H (2009). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (sup1): 3–63. doi:10.1080/13697130500148875. ISSN 1369-7137.
- Blanton MP, Xie Y, Dangott LJ, Cohen JB (February 1999). "The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface". Mol. Pharmacol. 55 (2): 269–78. PMID 9927618.